Efficacy of Gaviscon-Advance® in Suppressing Post-supper Acid-pocket and Night-time Acid-reflux in Obese Participants
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
A randomized, open-label study with antacid-control will be performed over 48 hours period by
continuous pH impedance and bravo capsule monitoring. Asymptomatic obese patients will be
separated into either groups according to alginate antacid group [Gaviscon Advance (GA)®,
Reckitt Benckiser, UK] and non antacid alginate group [simple antacid]. Both groups will be
studied for 48 hours using the ambulatory wireless capsule and pH impedance. Participants
according to their group will take either alginate antcid [Gaviscon Advance (GA)®, Reckitt
Benckiser, UK] or non alginate antacid [simple antacid] which has equivalent strength of
antacid after taking late night standardised meals.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Universiti Sains Malaysia University of Science Malaysia